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Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen
dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic
modality to treat prostate cancer. Androgen deprivation therapy has additional systemic eﬀects that include sexual dysfunction,
psychological changes and more important are the metabolic changes. Metabolic changes in particular include insulin resistance,
increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes. In this review we will focus on the
cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.
1.Introduction
Prostate cancer (PC) is one of the most common malig-
nancies in men and the second most common cause of
mortality among cancers in men after lung cancer. In re-
cent years, incidence of PC has been rising, probably due
to new and eﬀective screening guidelines. The Centers for
Disease Control (CDC) reports that in 2007 [1], (the most
recent year numbers are available) 223,307 men in the
United States were diagnosed with prostate cancer and
29,093 men in the United States died from prostate cancer.
Per the report of the National Cancer Institute, 2,311,000
have prostate cancer and the numbers projected for 2020
will be 3,266,000 [2]. Beside watchful waiting, standard
treatments for PC are surgery, radiation therapy, and
hormone therapy. Androgen dependence of PC was ﬁrst
described by Huggins et al. in 1941 [3]. Depletion of gonadal
testosterone through androgen deprivation therapy (ADT)
is the frontline treatment for advanced prostate cancer and
may be accomplished by medical or surgical castration. In
the current era, ADT is the primary therapy for localized
disease, as an adjunct to radiation therapy for high-risk
localized disease and as treatment for biochemical relapse
(prostate-speciﬁc antigen (PSA) rise only) after failure of
localized therapy, often with uncertain beneﬁts [4, 5].
The modalities of ADT include orchiectomy, radiation,
and medical castration (antiandrogens, LHRH agonists
LHRH antagonists), with latter being the most commonly
used. Continuous pituitary stimulation by GnRH agonists
overcomes endogenous pulsatile GnRH and suppresses LH
release, resulting in low serum testosterone, rather acting
as LHRH antagonists. Besides its beneﬁt, ADT is known to
cause several endocrine complications such as osteoporosis,
decreased libido, changes in cognition and mood, hot
ﬂushes, and gynecomastia [6]. In recent years, insulin resis-
tance,diabetes,dyslipidemia,adversebodycomposition,and
metabolic syndrome emerged as metabolic eﬀects of ADT,
which are contributing to increased cardiovascular mortality
in this population [7–12]. The purpose of the paper is to
familiarize the reader with clinical evidence on potential2 Prostate Cancer
metabolic complications of ADT and provide a perspective
to make educated decisions about the survival beneﬁt.
2. Evidence Acquisition
We performed MEDLINE searches (1950–2010) of English
literature using terms: androgen deprivation therapy, insulin
resistance, metabolic syndrome, diabetes, dyslipidemia, ad-
verse body composition, and hyperglycemia. The bibliog-
raphy of the literature found was reviewed for additional
relevant articles which were included in the review.
3. Body Mass Index (BMI), Insulin Resistance,
andProstateCancer
Epidemiologicstudieshaveshownthathigherserumlevelsof
insulinandinsulinresistanceareassociatedwithanincreased
risk of PC, even after adjustment for BMI, body fat, levels of
sex hormone, and insulin-like growth factor 1 (IGF-1) [13].
Becauseinsulinisaknowngrowthfactor,thereisapossibility
that insulin even may be responsible for the stimulation
of PC cells. Furthermore, insulin may increase the risk of
PC by stimulating IGF-1 synthesis [14], which is known to
stimulate growth of the prostate.
4. ADT andProstateCancer
PC continues to be a major health issue in the USA. One
in 6 men will develop prostate cancer at some point in
his life. Incidence of PC has been increasing probably sec-
ondary to the increased early detection rate with wider
use of PSA testing. Prostate cancer is largely an androgen-
sensitive disease. ADT is conventionally used for patients
with advanced disease. For localized disease, traditional
therapies were watchful waiting, external beam radiation
therapy, and radical prostatectomy. Studies have shown
that androgen deprivation may delay tumor progression
and improve survival after radical therapy [15, 16]. Two
main forms of ADT are medication (antiandrogens, LHRH
agonist) or surgical (orchiectomy), the former being much
more common [17]( Table 4). Medical ADT is achieved with
a luteinizing hormone-releasing hormone agonist such as
leuprolide (Lupron) or goserelin (Zoladex), or an antian-
drogen drug such as ﬂutamide or bicalutamide (Casodex),
or a combination of each [18]. ADT is now prescribed to
men without evidence of metastatic disease before beginning
radical therapy; men with prostate-speciﬁc antigen (PSA)
relapse after local therapy even in the absence of clinical or
radiographic evidence of metastatic disease, and for men
with evidence of metastatic disease. ADT is also used as
adjunct therapy for men undergoing radiation therapy for
high-risk localized disease. With the increase in the number
of prostate cancer cases seen in the United States, the use of
ADT as a form of treatment has continued to rise. Cancer of
the Prostate Strategic Urologic Endeavor (CaPSURE), which
is a national disease registry of men with prostate cancer, was
screened to identify patients who received treatment with
primary ADT (PADT) between 1989 and 2002 for clinically
localized disease (T1-T3, Nx/N0, Mx/M0) [19]. This study
noted that 14.1% with clinically localized disease received
primary ADT. In a similar study, the dominant forms
of hormone therapy were luteinizing hormone-releasing
hormone monotherapy (48.6%) and combined androgen
blockade (LHRH agonist and antiandrogens) (38.8%). At 5
years after the initiation of primary ADT, 67.3% of patients
still were receiving treatments with only androgen depriva-
tion [19]. Substantial variation exists in terms of primary
treatment selection for localized prostate cancer [20]. ADT
adjuvant to radiation therapy increases survival in men with
intermediate, high-risk, and locally advanced disease [21–
23]. Furthermore, there is a survival beneﬁt for men treated
with ADT after radical prostatectomy who also have lymph
nodeinvolvement[15].Moroteetal.[24]establishedadirect
relationship between testosterone increases and androgen-
independent progression. In a group of 73 men with prostate
cancer treated with 3 months of depot LHRH agonist, they
found that breakthrough responses, with increases of 20–
50ng/dL, occurred in 31%, while breakthrough responses
of >50ng/dL occurred in 25% of patients. Breakthrough
increasesintestosteronegreaterthanthisthresholdpredicted
a lower survival free of androgen-independent progression
[24].
5. AdverseEffects of ADT
The eﬀects of ADT include not only suppression of tumor
growth, but also adverse eﬀects on various bodily functions
and male health (Table 1). Besides sexual dysfunction and
vasomotor symptoms, ADT is known to cause osteoporosis,
anemia, gynecomastia, depression, and cognitive decline.
Also, it has been noticed recently that ADT increases the
incidence of the metabolic syndrome, insulin resistance, and
cardiovascular risk [32]. Normal serum testosterone levels
are required for normal virilization in men. Low testosterone
is associated with decreased libido and energy. Decreasing
serum testosterone can have a signiﬁcant negative impact on
qualityoflifeforpatientstreatedwithADT.Althougherectile
dysfunction is not uncommon after radical prostatectomy,
men who undergo ADT have a further decline in ability for
sexual intercourse and a decrease in sexual desire compared
with men who are not treated with ADT [33].
It has been well documented in the literature that male
hypogonadism is known to cause several endocrine compli-
cations such as osteoporosis, sexual dysfunction, changes in
cognition and mood, hot ﬂushes, gynecomastia, decreased
lean body and muscle strength, and quality of life [6].
Testosterone also plays a major role in muscle strength
and bone density. It has been also shown that ADT has a
signiﬁcant eﬀect on walking speed and physical performance
in men with prostate cancer [34]. Patients treated with ADT
experienced more symptoms, have worse fatigue [35], loss
of energy, emotional distress, and a lower overall quality of
life than men who deferred hormone therapy. Also it has
been shown that combined androgen blockade had a greater
adverse eﬀect on quality of life than monotherapy [36].
However, these eﬀects are well documented in the literatureProstate Cancer 3
Table 1: Eﬀects of ADT.
(1) Sexual dysfunction
(2) Decreased libido
(3) Impotence
(4) Decreased lean body mass
(5) Increased fat mass
(6) Decreased quality of life
(7) Gynecomastia
(8) Hot ﬂushes
(9) Insulin resistance
(10) Metabolic syndrome
(11) Increased TC
(12) Increased TG
(13) Increased LDL
(14) Changes in cognition
(15) Hyperglycemia
(16) Increased blood urea nitrogen
(17) Decreased red blood cell counts
(18) Decreased hemoglobin
(19) Decreased hematocrit
(20) Decreased uric acid
(21) Increased arterial pressure
(22) Increased arterial stiﬀness
(23) Increased leptin
(24) Increased resistin
(25) Increased cardiovascular mortality
and are not reviewed in detail here. In recent years, the focus
has turned towards metabolic side eﬀects of ADT and its
role in increasing cardiovascular mortality in this group of
patients.
6.Testosterone andMetabolicEffects
Testosterone has several desirable and undesirable eﬀects
on body metabolism. Nishiyama et al. showed that after
6 months of ADT, body weight, levels of fasting blood
sugar, serum total cholesterol, blood urea nitrogen, compen-
sated calcium, inorganic phosphorus, bone-speciﬁc alkaline
phosphatase, and compensated urinary deoxypyridinoline
increased signiﬁcantly. Peripheral red blood cell counts,
hemoglobin level, hematocrit, uric acid, and radial bone
density decreased signiﬁcantly [37]. It has been also shown
in a small trial that hypogonadism in males with prostate
cancer results in a rise in the augmentation of central
arterial pressure, suggesting large artery stiﬀening. Adverse
body compositional changes associated with rising insulin
concentrations suggest reduced insulin sensitivity. These
adverse hemodynamic and metabolic eﬀects may increase
cardiovascular risk in this patient group [25]. Testosterone
playsa signiﬁcantrolein metabolism ofadipose tissuestores.
It also has a role in direct regulation of vascular tone and
vascular compliance through both endothelial-dependent
and -independent mechanisms. Testosterone plays a crucial
role in body composition, regulating lean body mass,
insulin concentration, and sensitivity. Testosterone is directly
involved in mobilization of free fatty acids. Data suggest
that testosterone is negatively related to total cholesterol,
low-density lipoprotein, and triglyceride levels but positively
related to serum high-density lipoprotein. These beneﬁcial
eﬀects are thought to be mediated through its aromatization
to estrogen. Testosterone replacement in men results in an
improvement in insulin sensitivity by increasing glucose
disposal in the muscle [38]. Furthermore, testosterone
administration in men results in hyperplasia of Type 1
skeletal muscle ﬁbers, which are responsible for glucose
uptake [39, 40].
7. LipidPeroxidationandAntioxidant
Systems in ProstateCancer and Effect of
Antiandrogen Therapy
Oxidative damage occurs as a result of deﬁcient antioxidant
defensive mechanisms due to the eﬀect of endogenous and
exogenousfactors.Inastudytoevaluatetheeﬀectofprostate
cancerandantiandrogenic therapyonlipidperoxidation and
antioxidant systems, Iynem and associates [41]e v a l u a t e d
malondialdehyde level (MDA) as an indicator of lipid perox-
idation, erythrocyte glutathione (GSH) level as an indica-
tor of antioxidant state, glutathione reductase (GSH-Red),
glutathione peroxidase (GSH-Px), and glutathione-S-trans-
ferase (GST) as antioxidant enzymes and plasma vitamin E
level. They noted that erythrocyte GSH levels, the activities
of GSH-Red and GSH-Px, and plasma vitamin E levels were
found to be signiﬁcantly low (P<0.01, P<0.05, P ≤
0.001, and P ≤ 0.001 resp.), whereas plasma MDA levels
and erythrocyte GST activity were higher in patients with
prostate cancer when compared with the healthy subjects.
With antiandrogen therapy, there was a signiﬁcant decrease
in plasma MDA levels and signiﬁcant increase in erythrocyte
GST activity in the patient group [41], indicating a shift in
the oxidant-antioxidant balance towards the oxidative state
in patients with metastatic prostate cancer. Similar ﬁndings
were noted by Surapneni and Ramana [42].
8.ADT and Hyperglycemia, Insulin Resistance,
andDiabetes
There is a signiﬁcant negative correlation between total and
free testosterone levels and levels of fasting glucose, insulin,
leptin, and HOMA-IR (Table 2). Long-term ADT patients
are at risk for developing insulin resistance and hyper-
glycemia, thus leading to their increased risk of cardiovas-
cular disease. Testosterone deprivation was shown to cause
increased insulin concentration despite unchanged plasma
glucose,whichissuggestiveofinsulinresistance.Thisadverse
metabolicproﬁledevelopedindependentofageandBMIand
appearedtobeadirectresultofandrogendeprivation[12].A
short-term prospective study of 22 men with PC undergoing
ADT showed a signiﬁcant increase in insulin levels after
3 months of treatment compared with baseline; however,
there was no signiﬁcant change in plasma glucose levels [25].
Smith et al. reported that ADT signiﬁcantly increased fasting4 Prostate Cancer
Table 2: Eﬀects of ADT on glucose metabolism.
Duration HOMA Hyperglycemia Insulin level
Smith et al. [25] 3 months NR NS Increased 63% with ADT (P = 0.02)
Dockery et al. [26] 3 months NR NS Increased 63%∗
Basaria et al. [27] 12–101 months Higher with ADT∗ Higher in ADT∗ Higher with ADT∗
Smith et al. [28] 12 weeks NR NS Higher with ADT∗
NS: Not signiﬁcant; NR: Not reported; ∗P<0.001.
plasma insulin by 26% and decreased insulin sensitivity
by 13% [28]. Another short-term study showed that ADT
for 3 months resulted in a 63% increase in fasting insulin
levels without any changes in fasting glucose [26]. These
observations suggest that insulin resistance (manifested by
hyperinsulinemia) develops within a few months of starting
ADT; however, this hyperinsulinemia is suﬃcient to prevent
the development of hyperglycemia. It has been now also
shown that men on long-term ADT (at least 12 months)
were not only insulin resistant but also had developed frank
hyperglycemia [12]. Keating et al. in her observational study
(population-based cohort of 73,196) showed GnRH agonist
use was associated with increased risk of incident diabetes
with HR of 1.44 and CAD with HR 1.16. It is also associated
with MI with HR of 1.11 and sudden cardiac death with
HR 1.16 [10]. Men treated with orchiectomy were more
likely to develop diabetes but not coronary heart disease,
myocardial infarction, or sudden cardiac death in the same
study [10]. Basaria et al. showed that men taking ADT
had higher levels of leptin even after adjusting it for BMI
and there was a negative correlation between testosterone
levels and leptin levels. This indicates that low testosterone
levels were responsible directly for high leptin levels [12].
Furthermore, a recent longitudinal study showed that the
elevation in leptin levels with aging is a direct consequence
of decline in testosterone levels and not because of changes
in BMI [43]. Similarly, high leptin levels in men have been
associated with an increased risk of PC. Leptin may promote
the growth and survival of PC cells by several mechanisms.
Leptin upregulates the signaling of signal transducer and
activator of transcription 3, which has an antiapoptotic
role and is important for the growth and survival of PC
cells. Furthermore, it has been shown that leptin promotes
angiogenesis, which plays a crucial role in PC metastases.
This ﬁnding is supported by the fact that high-grade PC
lesions on pathology show strong immunoreactivity for
leptin receptor [12].
9. ADT andImmune Systemand
InﬂammatoryMarkers
Animal studies have shown that castration results in an
inﬂammatory state [44]. These adrenal glucocorticoid and
i m m u n eo v e rr e s p o n s e so b s e r v e di ng o n a d e c t o m i z e dm i c e
were shown to be reversed by testosterone treatment [44]. In
a study of men with hypogonadism (Klinefelter syndrome)
with autoimmune disorders, testosterone replacement has
improved immunological parameters [45]. These data sup-
port the notion that testosterone may inﬂuence immune cell
activation and prevent autoimmune disease development.
Using Cox proportional hazard models, C-reactive protein
(CRP) association with prostate cancer, no association was
noted by one group [46], and higher CRP is associated
with shorter survival [47]b yad i ﬀerent group of scientists,
suggesting inconsistent results [46, 47]. The recent report
by Smith et al showed in his 12 week prospective trial
that ADT is associated with decrease in insulin sensitivity
index and increase in adiponectin levels, but resistin, CRP
and plasminogen activator inhibitor type-1 did not changed
signiﬁcantly [48]. It also causes reduced vascular compliance
resulting from impaired endothelial release of mediators
such as nitric oxide contributes to arterial stiﬀening. How-
ever, data are not universal on this matter. Combined andro-
gen blockade with leuprolide and bicalutamide signiﬁcantly
increased serum adiponectin levels by 37.4%±7.2% from
baseline to week 12 (P<0.001) but did not alter the resistin,
CRP, or PAI-1 levels [48]. Interleukin-6 (IL-6) and CRP were
reported to be elevated in prostate cancer patients and IL-6
may potentially be involved in the development or progres-
sionofprostatecancer[49].Adiponectinlevelswerereported
lowerinPCthanincontrols[50].Inaprospectivestudy,CRP
appeared unrelated to prostate cancer risk [51]. In a recent
study to assess the tumoural presence and cellular location
of CRP using tissue microarray technology, Elsberger et al.
noted CRP presence in the cytoplasm and nucleus of selected
tumours [52]. Cytoplasmic CRP correlation positively with
metastases at diagnosis (P = 0.039), whereas nuclear CRP
presence correlation with metastases at relapse (P = 0.006).
A trend towards an increase in cytoplasmic and nuclear
CRPpresencefromhormonesensitivetohormonerefractory
tumours was noticed [52]. Since tumoural CRP is likely to
have a role in progression of prostate cancer, it was suggested
by authors that CRP is associated with increased presence
of metastases at the time of diagnosis and time of relapse
[52]. From the Apolipoprotein MOrtality RISk (AMORIS)
study with repeated measurements of CRP in a prospective
cohort study noted a positive trend between CRP and risk
of developing prostate cancer and concluded a link between
inﬂammatory markers and cancer risk [53].
10.ADTandDyslipidemia
The potential detrimental eﬀects of dyslipidemia in cardio-
vascular disease have been well appreciated over many years.
Recent studies have demonstrated that low testosteroneProstate Cancer 5
Table 3: Eﬀects of ADT on lipid metabolism.
Duration TC TG LDL HDL
Smith et al. [25] 3 months NS NS NS NS
Dockery et al. [26] 3 months ⇑ NS NS ⇑
Smith et al. [28]1 2 w e e k s ⇑⇑NS ⇑
Braga-Basaria et al. [11] 12–101 months ⇑ NS ⇑ NS
NS: Nonsigniﬁcant; ⇑: Increased; TC: Total Cholesterol; TG: Triglycerides;
LDL: Low density lipoprotein Cholesterol; HDL: High-density lipoprotein
Cholesterol.
concentrations are associated with lower levels of high
density lipoprotein cholesterol and higher triglyceride, total
cholesterol and low density lipoprotein concentrations [53].
This association persists even after adjusting for BMI. Diﬀer-
ent prospective and retrospective studies (Table 3), however,
showed slightly diﬀerent results. It has been shown consis-
tently in various studies that ADT increase total cholesterol
level. Some studies also showed increases in triglyceride level
[28, 54, 55] versus others, which did not show signiﬁcant
elevations in triglyceride level in the ADT group [25, 26, 53].
Although total cholesterol was often increased during ADT
therapy, HDL-C also found to increase in some studies,
which might decrease the adverse consequence of increased
total cholesterol. Most of the prospective trials fail to show
increases in LDL-C level, although a recent cross-sectional
study showed that men on long term ADT had signiﬁcantly
higher LDL cholesterol compared with the control group
[53]. Yannucci et al demonstrate that statistically signiﬁcant
increases in total cholesterol, triglyceride, LDL-C and HDL-
C can occur during the ﬁrst 6 months of ADT. Interestingly
these changes were observed even in patients on statin
therapy [54]. Another study showed orchiectomy caused
hypercholesterolemia and an increase in both total and LDL
apolipoprotein B. In that study, the high density lipoprotein
concentration was not aﬀected despite a reduction in plasma
testosterone [56]. Chen et al studied changes in plasma
cholesterols, lipoproteins, and apolipoproteins (Apo) B-100,
A-I, and A-II proﬁles over 2.5 years. They found signiﬁcant
decreasesofHDL-C,ApoA-IandApoA-IIandanincreaseof
triglyceridelevelsandVLDLassociatedwithADT[55].Inthe
same study, Apo B-100 levels were not statistically diﬀerent
between ADT and control group. Another long prospective
study in 40 men undergoing ADT for 48 weeks showed
increasesinalltotalcholesterol,lowdensitylipoprotein,high
density lipoprotein and triglyceride levels [29]. On other
hand, one short prospective study of 3 months duration did
not show any change in total cholesterol, LDL-C, HDL-C or
triglyceride level in contrast to most of the studies [25].
11. ADT and Body Composition
In healthy males, testosterone levels are inversely related to
the degree of central abdominal obesity (Table 1). In men
with low testosterone, improvement in visceral adiposity and
muscle mass has been reported with testosterone replace-
ment therapy. The mechanism for eﬀect of testosterone
on body fat metabolism is not very well deﬁned though
one hypothesis is that androgen receptors are known to be
present on visceral adipocytes. It is likely that testosterone
is directly involved in the mobilization of free fatty acids.
ADT causes a decrease in lean body mass and an increase
in fat body mass consistently [57]. Literature diﬀers in the
area of increased fat, subcutaneous versus abdominal fat. It
has been shown that PC patients have higher body weight, a
higher percentage of body fat, and are more likely to be obese
[30]. Increased fatness resulted primarily from accumulation
of subcutaneous tissue rather than intra-abdominal adipose
tissue [29]. ADT for prostate cancer results in accumulation
of both visceral and subcutaneous abdominal fat. Increased
visceral fat area appears more closely linked to testosterone
than estradiol deﬁciency. Increased insulin resistance may
arise secondary to visceral fat accumulation, rather than
as a direct result of sex steroid deﬁciency [58]. ADT may
indirectly aﬀect glucose and lipid metabolism by mediating
changesinbodycomposition,especiallyincreasedvisceralfat
accumulation. However, it has also been hypothesized that
testosterone can directly modulate hepatic and lipoprotein
lipases in visceral adipose tissue, aﬀecting insulin and lipid
levels [59]. It has been shown in various cross-sectional and
prospective trials that ADT in men with PC signiﬁcantly
decreases lean body mass and increases fat mass (Table 1).
Basaria et al. showed that men with PC undergoing ADT
have increased fat mass in both visceral and subcutaneous
areas compared with control patients [27]. Another short
term (3 months) study also conﬁrmed similar increase in
fat mass and a signiﬁcant reduction in lean body mass [25].
Chen et al. reported long-term followup (1–5 year) in men
undergoingADTtherapyandchangesinfatmassandobesity
prevalence. Unlike most other studies, the decrease in lean
body mass was not signiﬁcant but changes in weight and fat
masswerestatisticallysigniﬁcant[30].Long-termstudies(12
months followup) also showed similar results of decreased
leanbodymassandincreasedfatmassinpatientsundergoing
ADT for PC [31, 57]. Galv˜ ao et al. also reported lean body
mass and fat mass changes similar to others although they
also showed that increase in fat accumulation was in all
regional sites (upper limb, lower limb, trunk), with greater
changes for the limbs than trunk [60]. Most recent study
by Smith et al. showed 4.3 ± 1.3% increase in fat mass and
1.4 ± 0.5% decrease in lean body mass associated with men
undergoing ADT for a 3-month period [48]. In a study to
evaluate the eﬀect of hypogonadism secondary to ADT on
the vascular system reported that the changes in fat mass
correlate with increased insulin levels over a 3-month period
(r = 0.56; P = 0.013) [25].
12.ADT: CardiovascularDiseaseandMortality
Cardiovascular disease is the major cause of death world-
wide. It has been shown that premenopausal women have
lower risk of cardiovascular disease than postmenopausal
women.Theprotectiveroleofnormalestrogenlevelhasbeen
studied widely, however, till recently, limited information
was available for androgen deprivation and cardiovascular
risk. Several studies have reported an association between6 Prostate Cancer
Table 4: Eﬀect of ADT on body composition.
Duration Lean body mass Abdominal area BMI/Weight Fat mass
Basaria et al. [27] NS NR Higher in ADT group∗ Higher at total body, trunk
and extremities
Smith et al. [25] 3 months Decreased 1.7 kg,
P = 0.016 NR NR Increased 1.7Kg
Smith et al. [29] 4 months Decreased 2.7%∗ Increased by
3.9+1 .2%, P = 0.003 Increased by 2.4+0.8% Increased by 9.4+1 .7%∗
Chen et al. [30] 1–5 yr NS NR Higher in ADT group∗ Higher in ADT
Lee et al. [31] 12 months Decreased by 2%∗ NR NR Increased by 6.6%∗
NS: Not signiﬁcant; NR: Not reported ∗P<0.001.
Orchiectomy
Radiation
GnRH agonist or
antagonist
Hypogonadism
Abnormal body
composition:
Visceral adiposity
Decrease LBM
Abnormal lipoprotein
TC
TG
LDL
Insulin resistance
Diabetes
Metabolic
syndrome
Dyslipidemia
Increase
cardiovascular
mortality
Alter adipokines
leptin
resistin
Figure 1: Mechanisms that lead to diabetes and cardiovascular risk with prostate cancer therapy.
ADT and an increased risk of cardiovascular events, includ-
ing myocardial infarction and cardiovascular mortality [7, 9,
10, 61].
12.1. ADT: Potential Mechanisms of Cardiovascular Disease
(Figure 1). Prospective clinical trials have demonstrated that
ADT may increase cardiovascular disease risk by increasing
body weight, reducing insulin sensitivity, and/or resulting
in dyslipidemia [62]. Insulin itself to some extent acts as a
vascularhormoneandisknowntobeanimportantregulator
of vascular compliance in large arteries. It is known that
due to insulin resistance, ADT causes high insulin levels
at equal blood glucose level. As reported above, ADT has
been shown to be associated with the loss of lean body
mass and increase in adipose tissue, mainly visceral area.
These changes in body composition and insulin resistance
are associated with the increased risk of cardiovascular
disease. Although only moderate increase in risk of diabetes
and heart disease in men receiving ADT, it could have
substantial negative impact on the health of old age, frail
prostate cancer survivors, especially given the considerable
increases in its use among the men with local prostate
cancer. It has been shown that approximately half of men
with PC die of causes unrelated to the cancer itself, with
CVD being the most common noncancerous etiology. An
earlier report had shown that, after the deaths directly
attributable to PC and its complications, CVD was the
second leading cause of death (responsible for 27% of the
deaths) [63]. However, a recent report showed that non-
PC-related deaths now exceed PC-related mortality, with
CVDbeingthesinglemostcommoncauseofnon-PC-related
deaths [64]. Although prostate cancer speciﬁc mortality
is decreasing, there is little eﬀect on overall mortality in
this population, suggesting the possibility of an increasedProstate Cancer 7
risk of death from nonprostate cancer-related causes. Newly
diagnosed prostate cancer patients who received ADT for at
least 1 year were found to have a 20% higher risk of serious
cardiovascular morbidity compared with similar men who
did not receive ADT [9]. Efstathiou et al. have shown in a
large randomized trial of men treated with radiotherapy and
ADT that greater baseline BMI is independently associated
with higher prostate cancer speciﬁc mortality in men with
locally advanced prostate cancer. However, it is unclear
whether weight loss after prostate cancer diagnosis alters
the survival or not [65]. On other hand, evidence also
points toward obesity as an independent risk factor for
mortality and prostate cancer metastasis regardless of ADT
[66]. Beer et al. characterize changes in hemoglobin (Hb)
levels after the initiation of ADT in patients with previously
untreated,metastatic prostatecancer.Overall,3monthsafter
initiating ADT, the mean Hb level declined 0.54 g/dL. After
adjusting for potential confounders, including baseline Hb
level, a decline in Hb after 3 months of ADT was associated
independently with shorter survival (hazards ratio [HR],
1.10per1g/dLdecline;P = 0.0035)andshorterprogression-
free survival (HR, 1.08 per 1g/dL decline; P = 0.013) [67]
In another study, after a period of 2.5 years on ADT, four
patients out of twenty-four were found to be aﬀected by
coronary heart disease. In that study, ischemic coronary
arteriosclerosis with an incidence rate of 16.6% as caused
by prolonged ADT is mediated through changes in HDL
cholesterol, Apo A-I and Apo A-II proﬁles [55].
13. Conclusion
Prostate cancer is one of the leading causes of death in
men, but despite this, a substantial proportion of patients
withprostatecancerdie ofotherunrelatedcauses.Comorbid
conditions are common in this group, but a particularly
strong association has been noted between the presence
of cardiovascular disease and the eventual cause of death.
This raises the possibility that prostate cancer itself or the
treatment used in some way aggravates the natural course
of vascular disease. Decisions about ADT in PC should be
taken after weighing the beneﬁt of cancer-speciﬁc outcome
versus potential increase in risks of metabolic complication
and cardiovascular disease. Future research is needed to
deﬁne the situation for which beneﬁts of ADT outweigh
the risks. Because of substantial evidence, it is clear that
physicians need to discuss the potential cardiovascular and
metabolic risk of this therapy before starting the treatment
a st h eo v e r a l ls u r v i v a lb e n e ﬁ ti sn o ta se v i d e n t .F u t u r e
research is also required to identify populations at higher
risk of adverse eﬀect of ADT and for speciﬁc prevention
strategies in this group. Also, it is critically important to
determine the role of routine prevention measures like diet,
exercise, and lipid-lowering agents in reducing potential
cardiovascular risks. Until further evidence in prospective
trials is available, careful selection of patients, selective
screening of risk factors, focused eﬀorts to reduce cardiac
risks, and improvement in modiﬁable metabolic risk factors
m a ym i t i g a t es o m eo ft h ea d v e r s ee ﬀects of ADT.
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